Theresa Burkhard, Andrea M. Burden, Enriqueta Vallejo-Yagüe, et al: Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland BMJ Open, January 2022
Adrian Ciurea, Raphael Micheroli, Xenofon Baraliakos, et al: Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort RMD Open, January 2022
Theresa Burkhard, Andrea M. Burden, Enriqueta Vallejo-Yagüe, et al: Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients Rheumatology Advances in Practice, November 2021
Catherine Raptis, Diego Andrey, Christoph Berger et al.: Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic DiseasesACR, October 2021
Poster, October 2021
Christian A. Lechtenböhmer, Thomas Hügle et al.: Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis Arthritis Research & Therapy, October 2021
Enriqueta Vallejo-Yagüe, Andrea M. Burden, Theresa Burkard et al.: Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland MDPI, July 2021
Ulf Lindström, Michael Nissen et al.: Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration Annals of the Rheumatic Diseases, June 2021
Thomas Hügle, Axel Finckh, Almut Scherer et al.:Personalized Prediction of Disease Activity in Patients with Rheumatoid Arthritis Using an Adaptive Deep Neural Network. Plos One, June 2021
Michael J. Nissen , Burkhard Möller, Adrian Ciurea, et al.: Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors Arthritis Research & Therapy, June 2021
Diego Kyburz, Ulrich A Walker, Adrian Ciurea et al.: Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors Rheumatology, April 2021
Yomei Shaw, Axel Finckh, Ulrich A Walker, Adrian Ciurea et al.: Impact of assessing patient- reported outcomes with mobile apps on patient– provider interaction Rheumatology (Oxford), March 2021
Brigitte Michelsen, Michael Nissen, Burkhard Möller et al.: Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries Arthritis Care & Research, January 2021
Michael J Nissen, Matthias Jarlborg, Axel Finckh et al.: Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis Rheumatology (Oxford), January 2021
Céline Lamacchia, Zuleika Calderin Sollet, Axel Finckh et al.: Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease Rheumatology, December 2020
Regula Neuenschwander, Adrian Ciurea, et al.: Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort Arthritis Research & Therapy, October 2020
Adrian Ciurea, Axel Finckh, et al.: Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort Annals in Rheumatic Diseases, September 2020
Delphine S Courvoisier, Axel Finckh, et al.: The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries Rheumatology, August 2020
Adrian Ciurea, Michael Nissen et al.: Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration RMD Open, august 2020
Raphael Micheroli, Adrian Ciurea et al.: Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Annals in Rheumatic Diseases, June 2020
Axel Finckh, Pascal Zufferey et al.: Comparative Effectiveness of Antitumour Necrosis Factor Agents, Biologics With an Alternative Mode of Action and Tofacitinib in an Observational Cohort of Patients With Rheumatoid Arthritis in Switzerland. RMD Open, May 2020
Matthias Jarlborg, Michael Nissen et al.: Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Research and Therapy, May 2020
Matthew Thomas, Burkhard Moeller et al.: Tumour Necrosis Factor Inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases. The Journal of Rheumatology April 2020
Monika Hebeisen, Adrian Ciurea et al.: Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. Plos One, March 2020
Brigitte Michelsen, Adrian Ciurea et al.: Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology, January 2020
Yvette Meissner, Frauke Foerger et al.: European Network of Pregnancy Registers in Rheumatology (EuNeP)—an overview of procedures and data collection. Arthritis Research & Therapy, November 2019
CH Brahe, JM Nissen et al.: Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford), 2019 Oct 30, Epub ahead of print
Lykke Midtbøll Ørnbjerg, Adrian Ciurea et al.: Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. ARD Journals, Oktober 2019
Burkhard Möller, Michael Andor et al.: Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. Rheumatology (Oxford). 2019 Oct 19. pii: kez460. doi: 10.1093/rheumatology/kez460
Pascal Zufferey, Delphine S.Courvoisier et al.: Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real life. Joint Bone Spine, September 2019
Janick Rohrbach, Tobias Reinhard et al.: Bone erosion scoring for rheumatoid arthritis with deep convolutional neural networks. Computers & Electrical Engineering, August 2019
Anne Boel, Adrian Ciurea et al.: Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. ARD Journals, July 2019
Kim Lauper, Denis Mongin, Deshire Alpizar-Rodriguez et al.: Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology, June 2019
Monika Hebeisen, Adrian Ciurea et al.: Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis. PLOS|ONE, May 2019
Godehard A. Scholz, Alexander B. Leichtle, Burkhard Möller et al.: The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis. British Journal of Haematology, April 2019
Alpizar-Rodriguez D., Förger F. et al: Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort. Rheumatology, October 2018
Lauper K., Mongin D. et al: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD Open, Sept. 2018
Oude Voshaar M. A. H., Dourvoisier D., van de Laar M.A.F.J. et al: Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric. Quality of Life Research, September 2018
Lechtenböhmer C.A., Hügle T. et al: Influence of Disease Activity in Rheumatoid Arthritis on Radiographic Progression of concomitant Interphalangeal Joint Osteoarthritis. Arthritis and Rheumatology, August 2018
Didden E.M., Egger M., Finckh A. et al: Prediction of Real-World Drug Effectiveness Pre-Launch: Case Study in Rheumatoid Arthritis. Medical Decision Making, August 2018
Martinez-Prat L., Nissen M.J. et al: Comparison of serological Biomarkers in rheumatoid arthritis and their combination to improve Diagnostic Performance. Frontiers in Immunology, June 2018
Müller, R.B., von Kempis, J. et al: Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. Rheumatic and muscosceletal diseases (RMD) open, May 2018
Lauper K., Gabay C., et al: Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic DMARDs in patients with rheumatoid arthritis after the use of at least one biologic DMARD: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis. 2018; 0:1-7. doi: 10.1136/annrheumdis-2017-212845
Lauper K., Gabay C., et al: Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res. 2018, doi: 10.1002/acr.23567
Heinimann, K., von Kempis, J., et al.: Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. J. Clin. Med. 2018, 7, 57; doi:10.3390/jcm7030057
Hebeisen, M., Ciurea A., et al.: Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166
Zufferey P., Ziswiler HR, A. et al: Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study. The Journal of Rheumatology 2018; 45:3; doi:10.3899/jrheum.161193
Molnar, C., Scherer, A. et al.: TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2017 Sep 22. pii: annrheumdis-2017-211544. doi: 10.1136/annrheumdis-2017-211544. [Epub ahead of print]
Micheroli, R., Hebeisen, M., Ciurea, A. et al.: Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther. 2017 Jul 19;19(1):164. doi: 10.1186/s13075-017-1372-3.
Stekhoven, D., Scherer, A., Nissen, M.J. et al.: Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clin Rheumatol (2017), doi:10.1007/s10067-017-3637-2, 22 April 2017
Chaigne B et Finckh A et al: Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. Qual Life Res. 2017 Mar 11. doi: 10.1007/s11136-017-1534-4. [Epub ahead of print]
Chatzidionysiou K and Gabay C et al: Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. J Rheumatol. 2017 Feb;44(2):162-169. doi: 10.3899/jrheum.160460. Epub 2017 Jan 15.
Iannone F and Finckh A et al: Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol. 2016 Dec 14. PMID: 27966068 DOI: 10.1007/s10067-016-3505-5 [Epub ahead of print]
Mueller RB et al, “Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)”. Clin Rheumatol. 2016 Nov 12. [Epub ahead of print]
Nissen MJ et al: “The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.” Arthritis Rheumatol. 2016 Sep;68(9):2141-50. doi: 10.1002/art.39691.
Dourvoisier DS and Finckh A et al. “Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.” EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024.
Gottenberg JE and Finckh A et al., "Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis", Arthritis Rheumatology 2016, 68(6): 1346-52.
Mercer LK and Finckh A et al., "Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 Eurpean biologics registers", Ann Rheum Dis 2016 [Epub ahead of print].
Katerina Chatzidionysiou, Cem Gabay et al, “Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration” Arthritis Res Ther. 2016; 18: 50. Published online 2016 Feb 16.
Adrian Ciurea et al., "Does the reason for discontinuation of a firt TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort", Arthritis Research & Therapy 2016, 18:71.
ACR Washington, DC (11-16 November 2016)
EULAR London (8-11 June 2016)
Axel Finckh et al., "The impact of patient heterogeneity and socio-economic factors across nine European countries on abatacept retention in rheumatoid arthritis". RMD Open. 2015 Apr 30;1(1): PMID: 26509062.
Ulrich Walker et al., Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis, Rheumatology 2015 Aug 27. pii: kev297. [Epub ahead of print]
Cem Gabay et al., Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study, Ann Rheum Dis. 2015 Sep 15. pii: annrheumdis-2015-207760. doi: 10.1136/annrheumdis-2015-207760. [Epub ahead of print]
Cem Gabay et al., Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDsin rheumatoid arthritis: data from the Swiss Clinical Quality Management registry. Rheumatology, 2015 April 27. pii: kev019. [Epub ahead of print]
Adrian Ciurea et al., Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis. Ann Rheum Dis. 2015 Feb 9. pii: annrheumdis-2013-205133. doi: 10.1136/annrheumdis-2013-205133. [Epub ahead of print]
ACR San Francisco, November 6-11, 2015
ESBB - Biobanking Conference London, 29th September to Friday 2nd, 2015
EULAR Rome (10 - 13 June 2015)
Adrian Ciurea et al.,Treatment with Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Comparison Between Private Rheumatology Practices and Academic Centers in a Large Observational Cohort, The journal of Rheumatology, November 1, 2014, doi: 10.3899/jrheum.140229
Adrian Ciurea et al., Age at symptom onset in ankylosing spondylitis: is there a gender difference? Ann Rheum Dis, Published Online First: 7 August 2014
Elena Ciubotariu et al., Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs? The journal of Rheumatology, Published online before print July 15, 2014, doi: 10.3899/jrheum.130767
Rüdiger Müller et al., The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis, Clinical Rheumatology, 2014 Jul 15. [Epub ahead of print]
Pascal Zufferey et al., Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: Results of an observational cohort study, Joint Bone Spine, DOI: 10.1016/j.jbspin.2014.04.01
ACR Boston (14 – 19 November 2014)
EULAR Paris (11 - 14 June 2014)
Adrian Ciurea and Axel Finckh, Smoking and Spondyloarthritis, editorial, Joint Bone Spine 2013, 80: 234-5.
Pascal Zufferey et al., Recommendations for the use of ultrasound in rheumatoid arthritis: literature review and SONAR score experience, Swiss Med Wkly. 2013;143:w13861
Burkhard Möller et al., Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study, Ann. Rheum, published on December 19, 2013 as 10.1136/annrheumdis-2013-204078
Rüdiger Müller et al., Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort, Rheumatology (Oxford). 2013 Dec 17. [Epub ahead of print]
Pascal Zufferey et al., Ultrasound evaluation of synovitis in RA: Correlation with clinical disease activity and sensitivity to change in an observational cohort study, Joint Bone Spine, Available online 5 November 2013
Adrian Ciurea et al., Tumor necrosis factor-α inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort, Arthritis and Rheumatism 13-0025.R2; DOI: 10.1002/art.38140
Burkhard Möller et al., "Anaemia may add information to standardized disease activity assessment to predict radiographic damage in rheumatoid arthritis - a prospective cohort study", Ann Rheum Dis 2013 Mar 16. [Epub ahead of print]
ACR Congress, San Diego, 25–30 October 2013
SGR Interlaken (11 - 13 September 2013)
EULAR Madrid (12 - 15 June 2013)
Pascal Zufferey et al., "Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: Results from the Swiss SCQM registry", Joint Bone Spine, July 2013 Mar;80(2):160-4. doi: 10.1016/j.jbspin.2012.05.003. Epub 2012 Jul 4.
Axel Finckh et al.,"Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists", Ann Rheum Dis, March 2012
Delphine S Courvoisier et al., "Pain as an important predictor of psychosocial health in patients with rheumatoid arthritis." Arthritis care & research, Feb. 2012; 64(2):190-6
Sophie Martin Du Pan et al., "Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients", 2012 Jun;71(6):997-9. doi: 10.1136/annrheumdis-2011-200882. Epub 2012 Jan 30.
ACR/ARHP Annual Meeting Washington (9-14 November 2012)
Bechterew Symposium (3 November 2012)
SGR Geneva (19 - 21 September 2012)
EULAR Berlin (6 - 9 June 2012)
Katerina Chatzidionysiou et al., "Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration", Ann Rheum Dis 2011 Oct 4.
Katerina Chatzidionysiou et al., "Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.", Ann Rheum Dis. 2011 Sep;70(9):1575-80
Diego Kyburz et al., "The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study". Rheumatology (Oxford) 2011, Jun;50(6):1106-10. doi: 10.1093/rheumatology/keq424. Epub 2011 Jan 21.
Ulrich Walker et al., "Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion". 2011 Jan;50(1):243-4. doi: 10.1093/rheumatology/keq258. Epub 2010 Aug 17.
Axel Finckh at al., "Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients.". 2010 Jul;77(4):313-8. doi: 10.1016/j.jbspin.2010.02.021. Epub 2010 May 14.
Michael Nissen et al., "The effect of alcohol on radiographic progression in rheumatoid arthritis", 2010 May;62(5):1265-72. doi: 10.1002/art.27388.
Curtis JR et al., "A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries". Semin Arthritis Rheum. 2010 Aug;40(1):2-14.e1.
Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, "Comparison of drug retension rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis". Ann Rheum Dis. 2009 May 15; 61(5): 560-9.
Finckh A, Dehler S, Gabay C; SCQM doctors. "The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study." Ann Rheum Dis. 2009 Jan;68(1):33-9.
Axel Finckh et al., "Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent?". 2010 Feb;69(2):387-93. doi: 10.1136/ard.2008.105064. Epub 2009 May 4.
Finckh A , Dehler S, Costenbader K, Gabay C, on behalf of the SCQM-RA, "Cigarette smoking and radiographic progression in rheumatoid arthritis". Annals of the Rheumatic Diseases 2007; 66; 1066-1071.
Finckh A, Ciurea A, Brulhart L, Revaz S, Möller B, Dehler S, Kyburz D, Dudler J, Gabay C, on behalf of the SCQM-RA, "B-cell depletion may be more effective than switching to an alternative anti-TNF agent in RA patients with inadequate response to anti-TNF agents". Arthritis and Rheumatism 2007; May 2007; 56(5), 1417-23.
Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, for the physician of the SCQM-RA (* Authors have equally contributed), "Tolerance and effectiveness of anti-TNF-a therapies in elderly patients with rheumatoid arthritis. A population based cohort study". Arthritis and Rheumatism (AC&R) 2007 Apr 30; 57(4):679-685.
Finckh A, Simard J, Gabay C, Guerne PA, for the physician of the SCQM-RA, "Evidence for differential acquired drug resistance to anti-TNF agents in rheumatoid arthritis". Annals of Rheumatic Diseases 2006 Jun; 65(6):746-52.
Finckh A, Simard JF, Huang J, Duryea J, Liang M, Daneel S, Forster A, Gabay C, Guerne PA., "The effectiveness of anti-TNF therapy in preventing progressive radiographic joint damage in rheumatoid arthritis. A population based study". Arthritis and Rheumatism, 2006 Jan; 54(1):54-9. Pfizer Price 2006 for medical research: Clinical rheumatology and immunology.
Genta MS, Kardes H, Gabay C., "Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community". Joint Bone Spine, 2006 Jan; 73(1):51-6.
E. Uitz, J. Fransen , T. Langenegger and G. Stucki for the members of the SCQM-RA, "Clinical quality management in rheumatoid arthritis: putting theory into practice". Rheumatology 2000; 39:542-549.